| Předmět: |
|
| Zdroj: |
Diabetes Week; 2024, p2117-2117, 1p |
| Abstrakt: |
A recent study from Thomas Jefferson University explores the treatment of diabetic macular edema (DME). The study highlights the shift from laser therapy to anti-vascular endothelial growth factor (anti-VEGF) therapy and its impact on patient outcomes. The research suggests that less frequent dosing of anti-VEGF agents can maintain similar visual acuity and anatomical outcomes as traditional monthly injections. This finding could lead to greater adherence to treatment regimens, sustained visual function, and reduced healthcare costs. Further investigation is needed to understand the long-term effects of extended dosing intervals. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
